Delivery Order SPE2DB20D3103-SPE2DB25FN0R4

Award Date 3/14/25
Potential Completion Date 3/17/25
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $2,487.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of LINZESS 290 MCG CAPSULE UU 30S, a medical product, with a completion date of May 9, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order worth $1,615.02 with a Firm Fixed Price pricing type and an ultimate completion date of October 16, 2023. The contract is for the pharmaceutical product LINZESS 145 MCG CAPSULE UU 30S. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
This federal contract award, valued at $3,844.55, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product. The contract has an ultimate completion date of November 26, 2024 and is a Firm Fixed Price arrangement. It is not designated as a set-aside contract. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,150.08 firm fixed price delivery order is for the supply of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product. The contract has an ultimate completion date of February 19, 2025 and was awarded on February 18, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,280.72 firm fixed-price contract is for the delivery of LINZESS 145 MCG CAPSULE UU 30S, a prescription medication. The contract has an ultimate completion date of June 24, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $1,654.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 290 MCG CAPSULE, a pharmaceutical product. The contract has an ultimate completion date of December 30, 2024, and is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant...
This federal contract award, valued at $1,988.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product, with a completion date of September 27, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop...
This federal contract award, valued at $4,101.87, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for LINZESS 145 MCG Capsules, an essential pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This federal contract award, valued at $1,337.16, was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp. The contract is for the delivery of LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product, with a completion date of December 2, 2024. The contract type is a Delivery Order with a Firm Fixed Price pricing mechanism. This award is not associated with a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major...
This federal contract award, valued at $3,306.68, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product, with a completion date of July 10, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB25FN0R4
    Delivery Order

This federal contract award, valued at $1,239.04, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 17, 2025.

The contract provides for the delivery of LINZESS 72 MCG CAPSULE UU 30S, a pharmaceutical product, to support military healthcare programs. Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is the prime contractor and has no set-aside designation, indicating open competition. This contract award is associated with a larger Indefinite Delivery Contract (IDC) the company holds with the DLA, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 6/13/25, 9:57 AM